# US 2026/0060987 A1 · Methods and compositions for radioprotection and mitigation of radiation-induced injury using kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0060987 A1
- Document ID: US20260060987A1
- Status: Published application
- Kind: A1
- Application number: 19/318,283
- Filed: 2025-09-03
- Published: 2026-03-05
- Earliest claimed: 2024-09-03
- Applicants: Incyte Corporation
- Inventors: Albert Assad
- Web page: https://patentgrep.com/patent/US20260060987A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 39/00: General protective or antinoxious agents
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

The present application provides methods of treating a disease or disorder related to radiation exposure in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof which inhibits kinases such as JAK1, JAK1 and JAK2, or PI3Kδ.

## Claims

### Claim 1

A method of treating or preventing a disease or disorder related to radiation exposure in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof which inhibits JAK1, JAK1 and JAK2, or PI3Kδ.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound or pharmaceutically acceptable salt thereof inhibits JAK1 and JAK2, and is selective for JAK1 and JAK2 over JAK3 and TYK2.

### Claim 3 (depends on 2)

The method of claim 2, wherein the compound or pharmaceutically acceptable salt thereof is ruxolitinib, deuterated forms thereof, stereoisomers thereof, and/or pharmaceutically acceptable salts thereof.

### Claim at position 4

-9. (canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein the compound or pharmaceutically acceptable salt thereof inhibits JAK1, and is selective for JAK1 over JAK2, JAK3, and TYK2.

### Claim 11 (depends on 10)

The method of claim 10, wherein the compound or pharmaceutically acceptable salt thereof is itacitinib, deuterated forms thereof, stereoisomers thereof, and/or pharmaceutically acceptable salts thereof.

### Claim at position 7

-17. (canceled)

### Claim 18 (depends on 10)

The method of claim 10, wherein the compound or pharmaceutically acceptable salt thereof is povorcitinib, deuterated forms thereof, stereoisomers thereof, and/or pharmaceutically acceptable salts thereof.

### Claim at position 9

-24. (canceled)

### Claim 25 (depends on 1)

The method of claim 1, wherein the compound or pharmaceutically acceptable salt thereof inhibits PI3Kδ, and is selective for PI3Kδ over PI3Kα, PI3Kβ, and PI3Kγ.

### Claim 26 (depends on 25)

The method of claim 25, wherein the compound or pharmaceutically acceptable salt thereof is parsaclisib, deuterated forms thereof, stereoisomers thereof, and/or pharmaceutically acceptable salts thereof.

### Claim at position 12

-33. (canceled)

### Claim 34 (depends on 1)

The method of claim 1, wherein the radiation exposure is via non-therapeutic radiation.

### Claim 35 (depends on 1)

The method of claim 1, wherein the disease or disorder is acute radiation syndrome.

### Claim at position 15

-44. (canceled)

### Claim 45 (depends on 1)

The method of claim 1, wherein the radiation exposure is via therapeutic radiation.

### Claim at position 17

-59. (canceled)

### Claim 60 (depends on 1)

The method of claim 1, wherein the compound or pharmaceutically acceptable salt thereof is administered prior to exposure of the patient to radiation.

### Claim at position 19

-62. (canceled)

### Claim 63 (depends on 1)

The method of claim 1, wherein the compound or pharmaceutically acceptable salt thereof is administered after exposure of the patient to radiation.

### Claim at position 21

-70. (canceled)

### Claim 71 (depends on 1)

The method of claim 1, wherein the compound or pharmaceutically acceptable salt thereof is administered to the patient in a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier or excipient.

### Claim at position 23

-74. (canceled)

### Claim 75 (depends on 71)

The method of claim 71, wherein the administration is pulmonary.

### Claim 76

(canceled)

### Claim 77 (depends on 71)

The method of claim 71, wherein the administration is parenteral.

### Claim 78 (depends on 77)

The method of claim 77, wherein the parenteral administration is an intramuscular or subcutaneous injection.

### Claim 79 (depends on 77)

The method of claim 77, wherein the parenteral administration is in the form of a long acting depot formulation.

### Claim 80 (depends on 71)

The method of claim 71, wherein the administration is oral.

### Claim at position 30

-82. (canceled)

### Claim 83 (depends on 71)

The method of claim 71, wherein the administration is topical.

### Claim at position 32

-85. (canceled)

### Claim 86 (depends on 1)

The method of claim 1, further comprising administering one or more additional therapeutic agents.

### Claim at position 34

-107. (canceled)

### Claim 108

A method of increasing the survival rate of a patient exposed to radiation, comprising administering to the patient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof which inhibits JAK1, JAK1 and JAK2, or PI3Kδ.

### Claim at position 36

-120. (canceled)

### Claim 121

A kit comprising: (a) ruxolitinib, povorcitinib, itacitinib, parsaclisib, or a pharmaceutically acceptable salt of any of the aforementioned; and (b) instructions for using the ruxolitinib, povorcitinib, itacitinib, parsaclisib, or a pharmaceutically acceptable salt of any of the aforementioned for treating or preventing acute radiation syndrome of a patient.

### Claim at position 38

-123. (canceled)
